RADICAL PHARMACOLOGY · Free Radical Pharmacology: Generators, Targets and Therapeutic Implications
7РП — „Хора“ (Действия „Мария Кюри“)
- Период
- 2011-02-01 → 2015-01-31
- Финансиране от ЕС
- 100 000 €
- Участници
- 1
- Схема
- MC-IRG
Линиите свързват координатора с партньорите.
Накратко на български
Свободните радикали в тялото се изследват като мишени за лечение при инсулт и диабет. Контролът върху тяхните нива помага за намаляване на уврежданията в органите и подобряване на терапията при тези заболявания.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Free Radical Pharmacology: Generators, Targets and Therapeutic Implications
Life with oxygen comes at the expense of the formation of so-called reactive oxygen species that can cause harm in the body but are also used as signalling molecules. NO radicals are generally protective, superoxide antagonises NO and thus can cause disease. Innovative, mechanism-based and personalised therapies are based on (a) inhibiting oxygen radical formation (from NADPH oxidase, NOX), or (b) augmenting protective NO synthesis (by re-coupling NO synthase or re-activating the oxidatively damaged NO receptor, soluble guanylate cyclase (SGC). This project aimed and achieved to establish and validate these new approaches and to co-develop matching diagnostics. My team identified NOX4 and NOX5 as novel, mechanism-based therapeutic targets for ischemic stroke and diabetic nephropathy; NOX1, in diabetic atherosclerosis and retinopathy. Here inhibitory drugs proved to be beneficial and this principle is now co-developed with a Swedish biotech company for clinical development. Also a detrimental role for high levels of NO and potentiation with ROS was found suggesting a possible combination therapy. Moreover, on the beneficial side, sGC, the NO receptor was found to be reduced in stroke and could be activated by e new compound class, now also in clinical development. This also reduced stroke size suggesting even a triple therapy may be possible. These activities were scaled up to two major European networks as COST actions on NO (ENOG) and ROS (EU-ROS) as well as an Advanced Grant (RadMed), a EUROSTARS drug development programme and a H2020 application on ROS as a common mechanism explaining several comorbidities (COMMOX in PHC-03). Collectively, we achieved transfer of our research from Australia to Europe and scientific breakthroughs towards an entirely new approach to “oxidative stress” with high socio-economically relevant impact. We look forward taking this now to direct patient benefit.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Personalised Medicine is the next revolution in medicine. It is anticipated that we will see a dramatic shift towards predictive diagnostics and mechanism-based, individualised therapies. Cardiovascular diseases (CVD) are the leading causes of death and disability and in Europe cause over 4.3 million deaths (48%) per annum. Since the mechanisms of CVD are not understood, the majority of current therapeutic approaches are symptom-orientated and imprecise. Therefore, we need innovative strategies to develop mechanism-based drugs, i.e. drugs, which target the cause of disease. A prerequisite for this is a detailed knowledge on the causes of CVD. One such highly promising mechanism of CVD is oxidative stress, i.e. the increased occurrence of oxygen radicals, an area of utmost medical significance but where so far all clinical trials using antioxidant treatment have failed. Here three major aims are proposed: to identify targetable sources of radical signals that are relevant for CVD, to establish strategies for reversing the molecular damage caused by oxidative stress, and to develop new markers for diagnosis of CVD in humans and mechanism-based treatments. Thereby, a conceptual shift in treating oxidative stress will be achieved. In the long-term, this research will provide measurable outcomes in improved health, new products, and economic benefits by lowering the public health burden and facilitate the growth of biotechnology and pharmaceutical industries in Europe. This will result in a net decrease of health burden and will ensure sustainability of the healthcare system. This fellowship will also help to further attract leading international researchers to Europe to support the internationalisation of the European health and medical research, and to enhance EU’s reputation as place of excellence in biomedical research and translation.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITEIT MAASTRICHT · MaastrichtКоординаторНидерландия
Връзки
Данни: CORDIS, © Европейски съюз